Disease Landscape and Forecast 인사이트
종합적인 시장 정보와 실행 가능한 인사이트를 통해 장기적인 질병 전략을 최적화하세요.
Chronic Pain – Access & Reimbursement – Access & Reimbursement – Abuse-Deterrent Opioid Analgesics in Chronic Pain (US)
Abuse-deterrent formulations (ADFs) of opioid analgesics entered the U.S. pain market in 2010 as an attempt to slow the increasing rates of abuse/misuse and diversion stemming from chronic use of…
Chronic Pain | Access & Reimbursement | Abuse-Deterrent Opioid Analgesics in Chronic Pain | US | 2019
Abuse-deterrent formulations (ADFs) of opioid analgesics entered the U.S. pain market in 2010 as an attempt to slow the increasing rates of abuse/misuse and diversion stemming from chronic use of…
Epilepsy | Treatment Algorithms: Claims Data Analysis | Generalized-Onset Seizures | US | 2019
DRG epidemiologists estimate that 40% of epilepsy patients experience generalized-onset seizures (GOS). The most commonly prescribed early-line treatments for GOS are older antiepileptic drugs (…